Amendment to AOA/MOA

June 30, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) D(SaClaRl ISPt rCeOetD, E: 539871) Bandra (E), Mumbai - 400051 Mumbai- 400001 Sub Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 : (‘SEBI Listing Regulations’) Dear Sir / Madam, We wish to inform you that the Members of Thyrocare Technologies Limited (“the Company”), at the 26 Annual General Meeting (“AGM”) of the Company held on Tuesday, June 30, 2026, at the Corporate Office of the Company situated at D/37-3, TTC Industrial Area, MIDC, Turbhe, Navi Mumbai – 400703, have duly approved the amendment to the Memorandum of Association (“MOA”) of the Company, the details wPharetriceuolafr as re set outE risntw thhiele t Calbaulese bs elow: Amended clauses Substitution of MAIN OBJECTS OF THE THE OBJECTS TO BE PURSUED BY THE COMPANY ARE heading of Clause COMPANY TO BE PURSUED III(A) BY THE COMPANY ON ITS INCORPORATION Addition of Sub - 1B To carry on the business of establishing, setting clause 1B under up, acquiring, operating, managing or administering Clause III(A)(1) diagnostic facilities (including home collection), including but not limited to, clinical laboratories, radiology and pathology centres, collection centres, hospitals, clinics, polyclinics, research and healthcare facilities, and to provide healthcare and diagnostic services including pathological, radiological, biochemical, microbiological, immunological, genetic, cardiological and other medical investigations and testing services, and to undertake collection, handling, storage, transportation, processing and analysis of human, animal, plant, food, water, soil and other samples, tissues, body fluids, blood and allied materials for diagnostic, therapeutic, research or other purposes, in India or abroad, under its own brand or otherwise, including through online or digital platforms; and to develop, operate and manage healthcare, diagnostic and data- driven digital platforms, applications and portals; and to undertake teaching, training and imparting practical and theoretical knowledge in diagnostics, pathology, healthcare and allied fields; and further to manufacture, produce, assemble, process, procure, purchase, import, export, stock, distribute, market, sell, resell, lease, hire or otherwise deal in medical, diagnostic, healthcare, pharmaceutical, surgical, wellness equipment, devices, instruments, consumables, merchandise and allied products, including point of care devices, and to carry on such activities either on its own or in collaboration with third parties, partners, franchisees or service providers in India or abroad. Substitution of Object incidental or ancillary Matters which are necessary for furtherance of the heading of Clause to the attainment of main objects specified in Clause III(A) are: III(B) objects: Deletion of header Other Objects: Deleted in line with the Companies Act, 2013, as such of Clause III(C) i.e., clauses are now covered under Clause III(B) “Other Objects” Substitution of The liability of the members is The Liability of members is limited and this liability is Clause IV limited limited to the amount unpaid, if any, on the shares held by them. Statutory References to Companies To be replaced with corresponding provisions of the alignment Act, 1956 Companies Act, 2013 along with necessary consequential changes This disclosure is also being made available on the website of the Company at https://investor.thyrocare.com/. The above is submitted for your kind information and necessary records. Thyrocare Technologies Limited Y ours faithfully, Brijesh Kumar Company Secretary and Compliance Officer